Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany.

Menzen M, Berentzen TL, Catarig AM, Pieperhoff S, Simon J, Jacob S

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association4 Jan 2023Cited by 20 (Europe PMC)

PMID36599459PMCIDPMC10101737DOI10.1055/a-2007-2061PepBankPUB-36599459

Read at source PubMedAsk about this study

Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in German routine care, once-weekly semaglutide lowered mean HbA1c by 1.0 %-point from baseline to end of study.
In plain wordsIn adults with type 2 diabetes in routine care, semaglutide lowered HbA1c by 1.0 percentage point from baseline.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change
Study
n = 669
Comparator
Baseline
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · ~30 weeksAs given in this study (human).
Measurements
HbA1c change
−1 %-point
end of study
Source sentences
Summary
estimated mean changes in glycated haemoglobin and body weight from baseline to end-of-study were -1.0%point (-10.9 mmol/mol; P<0.0001)
2 context sentences(design, population, supporting numbers)
Summary · context
The prospective observational study was conducted at 93 clinical practices in adults with+≥ 1 documented glycated haemoglobin value ≤12 weeks before initiation of semaglutide.
Summary · context
Of 779 patients in the full analysis set, 669 (85.9%) completed the study on treatment with semaglutide, comprising the effectiveness analysis set.
Report a problemFND-3659945901
02HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in German routine care, once-weekly semaglutide lowered mean body weight by 4.5 kg (4.2%) from baseline to end of study.
In plain wordsIn adults with type 2 diabetes in routine care, semaglutide lowered body weight by 4.5 kg from baseline.
Peptide
Semaglutide
Outcome
DecreaseBody weight change
Study
n = 669
Comparator
Baseline
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · ~30 weeksAs given in this study (human).
Measurements
Body weight change
−4.5 kg
end of study
Body weight change
−4.2%
end of study
Source sentences
Summary
In this data set, estimated mean changes in glycated haemoglobin and body weight from baseline to end-of-study were -1.0%point (-10.9 mmol/mol; PP<0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
The prospective observational study was conducted at 93 clinical practices in adults with+≥ 1 documented glycated haemoglobin value ≤12 weeks before initiation of semaglutide.
Summary · context
Of 779 patients in the full analysis set, 669 (85.9%) completed the study on treatment with semaglutide, comprising the effectiveness analysis set.
Report a problemFND-3659945902
03HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in German routine care, patient-reported outcomes improved on once-weekly semaglutide.
In plain wordsIn adults with type 2 diabetes in routine care, patient-reported outcomes improved on semaglutide.
Peptide
Semaglutide
Outcome
IncreasePatient-reported outcomes
Study
n = 669
Comparator
Baseline
Analysis
Secondary
Outcome group
Exercise and physical function · Whole body
Studied dose
Dose not stated · ~30 weeksAs given in this study (human).
Source sentences
Summary
Improvements were observed in other secondary endpoints, including patient-reported outcomes.
2 context sentences(design, population, supporting numbers)
Summary · context
The prospective observational study was conducted at 93 clinical practices in adults with+≥ 1 documented glycated haemoglobin value ≤12 weeks before initiation of semaglutide.
Summary · context
Of 779 patients in the full analysis set, 669 (85.9%) completed the study on treatment with semaglutide, comprising the effectiveness analysis set.
Report a problemFND-3659945903
04HumanObservational studySafety outcome
In adults with type 2 diabetes in German routine care, no new safety concerns were identified with once-weekly semaglutide.
In plain wordsIn adults with type 2 diabetes in routine care, no new safety concerns were found with semaglutide.
Peptide
Semaglutide
Outcome
No significant changeSafety concerns
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · ~30 weeksAs given in this study (human).
Source sentences
Summary
No new safety concerns were identified.
2 context sentences(design, population, supporting numbers)
Summary · context
The prospective observational study was conducted at 93 clinical practices in adults with+≥ 1 documented glycated haemoglobin value ≤12 weeks before initiation of semaglutide.
Summary · context
Of 779 patients in the full analysis set, 669 (85.9%) completed the study on treatment with semaglutide, comprising the effectiveness analysis set.
Report a problemFND-3659945904

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.